1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Nanobiotix
  6. News
  7. All News
    NANO   FR0011341205

NANOBIOTIX

(NANO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
All news about NANOBIOTIX
05/18CORRECTING AND REPLACING : NANOBIOTIX Provides First Quarter Operational and Financial Upd..
BU
05/18NANOBIOTIX Provides First Quarter Operational and Financial Update
BU
05/17NANOBIOTIX to Present During the Jefferies Healthcare Conference in June 2022
BU
05/11NANOBIOTIX to Participate in Two Upcoming Investor Conferences
BU
05/04NANOBIOTIX to Announce First Quarter 2022 Financial Results on May 18, 2022
BU
05/02New Data Featuring NANOBIOTIX Lead Product Candidate NBTXR3 to Be Presented at the 2022..
BU
04/11Nanobiotix's Radiotherapy-activated Combination Therapy Shows Improved Anti-tumor Immun..
MT
04/11NANOBOTIX : New Preclinical Immunotherapy Data Show Boosted Anti-Tumor Immune Activation v..
PU
04/11NANOBOTIX :  New Preclinical Immunotherapy Data Show Boosted Anti-Tumor Immune Activation ..
BU
04/11Nanobiotix S.A. Announces New Data from an Open-Label Preclinical Study Evaluating the ..
CI
04/11NANOBIOTIX : Press Release, dated April 08, 2022 - Form 6-K
PU
04/08NANOBIOTIX Announces Filing of the 2021 Universal Registration Document and the 2021 An..
BU
04/08NANOBIOTIX : Form 20-f/a
PU
03/30NANOBIOTIX : Inside Information / Other news releases
PU
03/30NANOBIOTIX : Provides Business Update and Reports Full Year 2021 Financial Results - Form ..
PU
03/30Nanobiotix S.A. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
03/30 NANOBIOTIX Provides Business Update and Reports Full Year 2021 Financial Results
BU
03/16NANOBIOTIX : to Announce Full Year 2021 Financial Results on March 30, 2022 - Form 6-K
PU
03/16NANOBIOTIX to Announce Full Year 2021 Financial Results on March 30, 2022
BU
02/10NANOBIOTIX : Inside Information / Other news releases
PU
02/09Nanobiotix's Pancreatic Cancer Treatment Shows No Toxicity In Early-Stage Trial Patient
MT
02/09NANOBIOTIX : Announces Publication of New Clinical Case Study Highlighting First Patient E..
PU
02/09Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient ..
BU
02/09Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient ..
CI
02/04NANOBIOTIX : OPERATING AND FINANCIAL REVIEW AND PROSPECTS - Form 6-K
PU
01/26NANOBIOTIX : Announces Publication of New Preclinical Immunotherapy Data Showcasing the Co..
PU
01/26NANOBIOTIX Announces Publication of New Preclinical Immunotherapy Data Showcasing the C..
BU
01/26Nanobiotix S.A. Announces Publication of New Preclinical Immunotherapy Data Showcasing ..
CI
01/10NANOBIOTIX : Provides Corporate Update and Highlights Key 2022 Milestone Targets - Form 6-..
PU
01/10NANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone Targets
BU
01/05Nanobiotix Enrolls First Patient In Late-Stage Trial For Head, Neck Cancer Treatment
MT
01/05Nanobiotix Enrolls First Patient in Phase 3 Study of Head, Neck Cancer Treatment
MT
01/05NANOBIOTIX : Announces First Patient Enrolled in NANORAY-312 Global Phase III Registration..
PU
01/05NANOBIOTIX Announces First Patient Enrolled in NANORAY-312 Global Phase III Registratio..
BU
01/05Nanobiotix S.A. Announces First Patient Enrolled in NANORAY-312 Global Phase III Regist..
CI
01/04Nanobiotix Announces Participation at Three Virtual Investor Conferences in January 202..
BU
2021NANOBIOTIX : to Present at the 4th Annual Evercore ISI HealthCONx Conference - Form 6-K
PU
2021NANOBIOTIX to Present at the 4th Annual Evercore ISI HealthCONx Conference
BU
2021GLOBAL MARKETS LIVE : Rotschild, Adidas, Allianz, Apple, AstraZeneca...
2021Nanobiotix's Cancer Drug Shows Potential As Combination Therapy In Preclinical Study
MT
2021NANOBIOTIX Announces New Preclinical Data Highlighting NBTXR3 Immune Priming and Checkp..
PU
2021NANOBIOTIX Announces New Preclinical Data Highlighting NBTXR3 Immune Priming and Checkp..
BU
2021Nanobiotix S.A. Announces New Preclinical Data Highlighting NBTXR3 Immune Priming and C..
CI
2021GLOBAL MARKETS LIVE : Electronic Arts, Credit Suisse, Novartis, Merck, Tesla...
2021NANOBIOTIX to Participate in a Fireside Chat at the Jefferies London Healthcare Confere..
PU
2021NANOBIOTIX to Participate in a Fireside Chat at the Jefferies London Healthcare Confere..
BU
2021GLOBAL MARKETS LIVE : HSBC, PayPal, Tesla, Daimler, Intel...
2021NANOBIOTIX : Announces 18.1 Month Median Overall Survival for 41 Evaluable Elderly and Fra..
PU
2021NANOBIOTIX : Unveils First Survival Data From Head, Neck Cancer Treatment
MT
2021NANOBIOTIX : Announces 18.1 Month Median Overall Survival for 41 Evaluable Elderly and Fra..
BU
2021NANOBIOTIX Announces 18.1 Month Median Overall Survival for 41 Evaluable Elderly and Fr..
CI
2021NANOBIOTIX : Provides Third Quarter Operational and Financial Update - Form 6-K
PU
2021NANOBIOTIX : Provides Third Quarter Operational and Financial Update
BU
2021NANOBIOTIX : In accordance with Articles L.233-8 II of the French Commercial Code and 223-..
PU
2021NANOBIOTIX : to Present First Survival Data From Priority Head and Neck Cancer Program Amo..
PU
2021NANOBIOTIX : to Present First Survival Data From Priority Head and Neck Cancer Program Amo..
BU
2021GLOBAL MARKETS LIVE : Sanofi, ASML, Apple, United Airlines, Netflix...
2021NANOBIOTIX : Announces Red Journal Publication of Preclinical Data Showing Radioenhancer N..
PU
2021NANOBIOTIX : Announces Red Journal Publication of Preclinical Data Showing Radioenhancer N..
BU
2021Nanobiotix S.A. Announces Red Journal Publication of Preclinical Data Showing Radioenha..
CI
2021NANOBIOTIX : In accordance with Articles L.233-8 II of the French Commercial Code and 223-..
PU
2021NANOBIOTIX : LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (Form 6-K)
PU
2021NANOBIOTIX : PROVIDES BUSINESS UPDATE AND REPORTS FINANCIAL RESULTS FOR THE FIRST HALF OF ..
PU
2021NANOBIOTIX S A : Provides Business Update and Reports Financial Results for the First Half..
BU
2021Nanobiotix S.A. Reports Earnings Results for the Half Year Ended June 30, 2021
CI
2021GLOBAL MARKETS LIVE : Airbus, Ford, Intel, Apple, PayPal...
2021NANOBIOTIX : TO PRESENT AT THE H.C. WAINWRIGHT 23rd ANNUAL GLOBAL INVESTMENT CONFERENCE (F..
PU
2021NANOBIOTIX S A : to Present at the H.C. Wainwright 23rd Annual Global Investment Conferenc..
BU
2021GLOBAL MARKETS LIVE : Netflix, Novartis, Tesla, Autodesk, AMC...
2021NANOBIOTIX : PROVIDES SECOND QUARTER OPERATIONAL AND FINANCIAL UPDATE (Form 6-K)
PU
2021NANOBIOTIX S A : Provides Second Quarter Operational and Financial Update
BU
2021GLOBAL MARKETS LIVE : Amazon, The Gap, Fod, Lockheed Martin, CureVac...
2021NANOBIOTIX : ANNOUNCES INITIATION OF NEW CLINICAL STUDY EVALUATING NBTXR3 IN LUNG CANCER (..
PU
2021NANOBIOTIX S A : Begins Early-Stage Study of Drug Candidate for Lung Cancer
MT
2021NANOBIOTIX : Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer
BU
1  2  3  4  5  6  7Next